LGVN
Longeveron Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.78
−0.28%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.78
From 52W high−84.70%
Volume2111.00
Market cap$5.66M
P/E (TTM)—
P/S (TTM)4.8x
Div yield—
Key dataNov 4, 2026
Open
$1.78
From 52W high
−84.70%
Volume
2111.00
Market cap
$5.66M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
34.5
MomentumView details →
1D Return
−0.28%
YTD Return
−65.22%
SummaryUpdated Jun 1, 2026
Longeveron Inc. (NASDAQ:LGVN) is a clinical-stage biotechnology company founded in 2014 and based in Miami, Florida. The company went public in February 2021 and focuses on developing cellular therapies for aging-related and life-threatening conditions. Longeveron's primary focus is advancing its lead investigational product, LOMECEL-B, a cell-based therapy derived from bone marrow of young healthy adult donors, through various clinical trials targeting rare diseases and age-related conditions.
Similar companies
Latest newsMore news →
Longeveron retained Lucid Capital Markets as financial advisor to explore potential strategic opportunities, including a potential business combination.7d agoLongeveron announced updated ELPIS II trial results, reporting 8 major adverse cardiac events in the standard-of-care arm versus 1 in the laromestrocel arm (P=0.043); the trial had not met its primary endpoint of increased right ventricular ejection fraction at month 12.9d agoLongeveron Inc. reported that Chief Medical Officer Dr. Nataliya Agafonova departed, effective October 14, 2026.21d ago